Ligand Pharmaceuticals Stock Price, News & Analysis (NASDAQ:LGND)

$135.80 0.74 (0.55 %)
(As of 12/13/2017 01:49 PM ET)
Previous Close$135.06
Today's Range$135.13 - $136.75
52-Week Range$95.08 - $149.31
Volume192,200 shs
Average Volume246,585 shs
Market Capitalization$2.85 billion
P/E Ratio101.55
Dividend YieldN/A
Beta0.91

About Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals logoLigand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.

Receive LGND News and Ratings via Email

Sign-up to receive the latest news and ratings for LGND and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:LGND
CUSIP53220K50
Phone858-550-7500

Debt

Debt-to-Equity Ratio0.05%
Current Ratio0.97%
Quick Ratio0.95%

Price-To-Earnings

Trailing P/E Ratio101.55
Forward P/E Ratio57.30
P/E Growth2.08

Sales & Book Value

Annual Sales$108.97 million
Price / Sales26.30
Cash Flow$0.97 per share
Price / Cash139.79
Book Value$16.33 per share
Price / Book8.32

Profitability

Trailing EPS$0.69
Net Income$-1,630,000.00
Net Margins12.76%
Return on Equity7.83%
Return on Assets4.64%

Miscellaneous

Employees22
Outstanding Shares21,100,000

Ligand Pharmaceuticals (NASDAQ:LGND) Frequently Asked Questions

What is Ligand Pharmaceuticals' stock symbol?

Ligand Pharmaceuticals trades on the NASDAQ under the ticker symbol "LGND."

How were Ligand Pharmaceuticals' earnings last quarter?

Ligand Pharmaceuticals Inc. (NASDAQ:LGND) announced its quarterly earnings results on Thursday, November, 9th. The biotechnology company reported $0.69 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.37 by $0.32. The biotechnology company earned $33.38 million during the quarter, compared to the consensus estimate of $31.04 million. Ligand Pharmaceuticals had a return on equity of 7.83% and a net margin of 12.76%. The firm's quarterly revenue was up 54.4% compared to the same quarter last year. During the same period in the prior year, the company posted $0.62 earnings per share. View Ligand Pharmaceuticals' Earnings History.

When will Ligand Pharmaceuticals make its next earnings announcement?

Ligand Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 22nd 2018. View Earnings Estimates for Ligand Pharmaceuticals.

What guidance has Ligand Pharmaceuticals issued on next quarter's earnings?

Ligand Pharmaceuticals updated its FY17 earnings guidance on Tuesday, November, 14th. The company provided earnings per share guidance of $2.95-3.00 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.99. The company issued revenue guidance of $134-136 million, compared to the consensus revenue estimate of $136.89 million.

Where is Ligand Pharmaceuticals' stock going? Where will Ligand Pharmaceuticals' stock price be in 2017?

5 analysts have issued 1 year price targets for Ligand Pharmaceuticals' shares. Their forecasts range from $105.00 to $170.00. On average, they anticipate Ligand Pharmaceuticals' share price to reach $146.60 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals.

What are Wall Street analysts saying about Ligand Pharmaceuticals stock?

Here are some recent quotes from research analysts about Ligand Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Ligand reported better-than-expected results in the third quarter of 2017 with both earnings and revenues beating estimates. The company’s Captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. Also, with regard to Ligand’s internal pipeline, there are several candidates in development that could bring in future licensing opportunities. Additionally, the company’s entry into the Medical Devices Segment with the acquisition of multiple programs owned by CorMatrix is encouraging. Shares of Ligand have outperformed the broader industry this year so far. However, the company derives a substantial portion of its revenues from royalties associated with the sales of Promacta and Kyprolis. Any setback related to either of these two products could leave a substantial impact." (11/30/2017)
  • 2. HC Wainwright analysts commented, "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business model.Ligand seeks out value-based acquisitions of companies and technologies that have led to both current and anticipated revenue streams, Pantginis commented in his initiation note. This has also resulted in the company's reputation of reporting sustained profitability.Ligand is also an early pioneer of contingent value rights for its acquisitions, the analyst continued. As such, earnings growth is supported by the company's increasing royalty streams that are also a "significant spreading out of risk" (9/5/2017)

Who are some of Ligand Pharmaceuticals' key competitors?

Who are Ligand Pharmaceuticals' key executives?

Ligand Pharmaceuticals' management team includes the folowing people:

  • Matthew W. Foehr, President, Chief Operating Officer
  • John L. Higgins, Chief Executive Officer, Director
  • Matthew E. Korenberg, Chief Financial Officer, Vice President - Finance
  • Charles S. Berkman J.D., Vice President, General Counsel, Secretary
  • John W. Kozarich, Non-Executive Independent Chairman of the Board
  • Nancy Ryan Gray, Director
  • Jason M. Aryeh, Independent Director
  • Todd C. Davis, Independent Director
  • John L. LaMattina Ph.D., Independent Director

Who owns Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Janus Henderson Group PLC (3.58%), Victory Capital Management Inc. (3.14%), Eagle Asset Management Inc. (2.49%), Macquarie Group Ltd. (2.35%), Stephens Investment Management Group LLC (2.29%) and Oak Ridge Investments LLC (2.22%). Company insiders that own Ligand Pharmaceuticals stock include Charles S Berkman, Jason Aryeh, John L Higgins, John W Kozarich, Matthew E Korenberg, Matthew W Foehr and Melanie J Herman. View Institutional Ownership Trends for Ligand Pharmaceuticals.

Who sold Ligand Pharmaceuticals stock? Who is selling Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Oak Ridge Investments LLC, RK Capital Management LLC, Mesirow Financial Investment Management Equity Management, State of New Jersey Common Pension Fund D, Dimensional Fund Advisors LP, Cortina Asset Management LLC, Victory Capital Management Inc. and Kornitzer Capital Management Inc. KS. Company insiders that have sold Ligand Pharmaceuticals company stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins, John W Kozarich, Matthew E Korenberg and Matthew W Foehr. View Insider Buying and Selling for Ligand Pharmaceuticals.

Who bought Ligand Pharmaceuticals stock? Who is buying Ligand Pharmaceuticals stock?

Ligand Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Stifel Financial Corp, Nationwide Fund Advisors, Conestoga Capital Advisors LLC, Ameriprise Financial Inc., Janney Montgomery Scott LLC, Prudential Financial Inc. and Strs Ohio. View Insider Buying and Selling for Ligand Pharmaceuticals.

How do I buy Ligand Pharmaceuticals stock?

Shares of Ligand Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Ligand Pharmaceuticals' stock price today?

One share of Ligand Pharmaceuticals stock can currently be purchased for approximately $135.80.

How big of a company is Ligand Pharmaceuticals?

Ligand Pharmaceuticals has a market capitalization of $2.85 billion and generates $108.97 million in revenue each year. The biotechnology company earns $-1,630,000.00 in net income (profit) each year or $0.69 on an earnings per share basis. Ligand Pharmaceuticals employs 22 workers across the globe.

How can I contact Ligand Pharmaceuticals?

Ligand Pharmaceuticals' mailing address is 3911 SORRENTO VALLEY BLVD SUITE 110, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-550-7500 or via email at [email protected]


MarketBeat Community Rating for Ligand Pharmaceuticals (LGND)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  298 (Vote Outperform)
Underperform Votes:  171 (Vote Underperform)
Total Votes:  469
MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Ligand Pharmaceuticals (NASDAQ:LGND) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.672.802.802.83
Ratings Breakdown: 1 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $143.00$140.17$135.17$137.14
Price Target Upside: 9.80% upside1.84% downside4.84% upside20.89% upside

Ligand Pharmaceuticals (NASDAQ:LGND) Consensus Price Target History

Price Target History for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ:LGND) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/28/2017HC WainwrightSet Price TargetBuy$163.00LowView Rating Details
11/20/2017Deutsche BankDowngradeHold -> Sell$105.00N/AView Rating Details
11/15/2017Craig HallumReiterated RatingBuy$160.00 -> $170.00N/AView Rating Details
11/13/2017Roth CapitalSet Price TargetBuy$158.00N/AView Rating Details
8/9/2017StephensReiterated RatingOverweight$125.00 -> $137.00LowView Rating Details
9/28/2016CJS SecuritiesLower Price TargetOutperform$130.00 -> $125.00N/AView Rating Details
3/11/2016SidotiInitiated CoverageBuy$140.00N/AView Rating Details
(Data available from 12/13/2015 forward)

Earnings

Ligand Pharmaceuticals (NASDAQ:LGND) Earnings History and Estimates Chart

Earnings by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ LGND) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/21/2018$1.06N/AView Earnings Details
11/9/2017Q3 2017$0.37$0.69$31.04 million$33.38 millionViewN/AView Earnings Details
8/7/2017Q2 2017$0.25$0.67$24.40 million$28.00 millionViewListenView Earnings Details
5/9/2017Q1 2017$0.55$0.39$30.25 million$29.27 millionViewListenView Earnings Details
2/23/2017Q416$1.19($0.15)$40.34 million$38.20 millionViewN/AView Earnings Details
11/3/2016Q316$0.59$0.62$23.64 million$21.62 millionViewN/AView Earnings Details
8/4/2016Q216$0.40$0.50$18.12 million$19.50 millionViewN/AView Earnings Details
5/4/2016Q116$0.67$0.97$26.45 million$29.60 millionViewN/AView Earnings Details
2/10/2016Q415$0.51$0.66$24.71 million$21.20 millionViewListenView Earnings Details
11/9/2015Q315$0.42$0.56$17.80 million$17.70 millionViewN/AView Earnings Details
8/4/2015Q215$0.40$1.63$17.00 million$18.42 millionViewN/AView Earnings Details
5/11/2015Q115$0.12$0.33$13.50 million$14.60 millionViewListenView Earnings Details
2/9/2015Q414$0.48$0.48$23.88 million$23.00 millionViewN/AView Earnings Details
10/27/2014Q314$0.21$0.19$14.60 million$15.00 millionViewListenView Earnings Details
8/4/2014Q214$0.14$0.24$9.73 million$10.60 millionViewN/AView Earnings Details
5/7/2014Q114$0.25$0.35$13.63 million$16.00 millionViewN/AView Earnings Details
2/11/2014Q413$0.19$0.35$13.72 million$14.70 millionViewN/AView Earnings Details
10/30/2013Q213$0.07$0.12$10.81 million$13.00 millionViewN/AView Earnings Details
8/1/2013Q2 2013$0.06$0.07$9.48 million$9.58 millionViewN/AView Earnings Details
5/8/2013Q1 2013$0.09$0.16$10.00 million$11.70 millionViewN/AView Earnings Details
2/13/2013Q4 2012$0.19$12.90 million$13.60 millionViewN/AView Earnings Details
11/5/2012Q312$0.04($0.01)$8.40 million$6.40 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Ligand Pharmaceuticals (NASDAQ:LGND) Earnings Estimates

2017 EPS Consensus Estimate: $2.60
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.43$0.43$0.43
Q2 20171$0.60$0.60$0.60
Q3 20171$0.75$0.75$0.75
Q4 20171$0.82$0.82$0.82
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Ligand Pharmaceuticals (NASDAQ:LGND)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Ligand Pharmaceuticals (NASDAQ LGND) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 8.30%
Insider Trades by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)
Insider Trades by Quarter for Ligand Pharmaceuticals (NASDAQ:LGND)

Ligand Pharmaceuticals (NASDAQ LGND) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/17/2017Matthew E KorenbergVPSell6,559$142.63$935,510.17View SEC Filing  
11/16/2017John L HigginsCEOSell5,269$142.53$750,990.57View SEC Filing  
11/16/2017John W KozarichDirectorSell5,000$141.71$708,550.00View SEC Filing  
9/5/2017John L HigginsCEOSell5,000$130.00$650,000.00View SEC Filing  
8/23/2017Jason AryehDirectorSell2,000$127.99$255,980.00View SEC Filing  
8/9/2017Charles S BerkmanVPSell18,625$126.96$2,364,630.00View SEC Filing  
8/9/2017Matthew W FoehrInsiderSell6,100$127.51$777,811.00View SEC Filing  
8/8/2017John L HigginsCEOSell5,483$125.00$685,375.00View SEC Filing  
6/21/2017John L HigginsCEOSell4,666$120.00$559,920.00View SEC Filing  
6/9/2017John L HigginsCEOSell12,000$114.87$1,378,440.00View SEC Filing  
5/12/2017Jason AryehDirectorSell37,247$110.76$4,125,477.72View SEC Filing  
5/12/2017Matthew W FoehrInsiderSell5,621$112.20$630,676.20View SEC Filing  
3/20/2017John L HigginsCEOSell4,000$109.10$436,400.00View SEC Filing  
3/2/2017Matthew W FoehrInsiderSell6,879$103.39$711,219.81View SEC Filing  
2/28/2017Jason AryehDirectorSell32,000$106.35$3,403,200.00View SEC Filing  
11/25/2016Jason AryehDirectorSell18,479$107.31$1,982,981.49View SEC Filing  
11/18/2016Jason AryehDirectorSell6,330$105.28$666,422.40View SEC Filing  
9/22/2016John L HigginsCEOSell3,000$117.34$352,020.00View SEC Filing  
9/7/2016John W KozarichDirectorSell1,000$115.00$115,000.00View SEC Filing  
9/1/2016John W KozarichDirectorSell1,666$105.40$175,596.40View SEC Filing  
8/1/2016John W KozarichDirectorSell1,000$137.57$137,570.00View SEC Filing  
7/1/2016John W KozarichDirectorSell1,000$121.40$121,400.00View SEC Filing  
6/1/2016John W KozarichDirectorSell1,000$117.42$117,420.00View SEC Filing  
5/18/2016Melanie J HermanDirectorSell334$120.50$40,247.00View SEC Filing  
5/6/2016Jason AryehDirectorSell25,000$119.20$2,980,000.00View SEC Filing  
5/2/2016John W KozarichDirectorSell1,000$121.57$121,570.00View SEC Filing  
4/6/2016John W KozarichDirectorSell5,000$115.00$575,000.00View SEC Filing  
3/17/2016Matthew W FoehrCOOSell6,400$96.70$618,880.00View SEC Filing  
3/8/2016Jason AryehDirectorSell6,129$101.18$620,132.22View SEC Filing  
3/7/2016John L HigginsCEOSell10,833$102.47$1,110,057.51View SEC Filing  
1/20/2016John W. KozarichDirectorSell1,666$94.94$158,170.04View SEC Filing  
11/11/2015Melanie J. HermanDirectorSell7,719$101.00$779,619.00View SEC Filing  
8/17/2015David M KnottDirectorSell4,000$95.98$383,920.00View SEC Filing  
8/13/2015David M KnottDirectorSell49,800$96.26$4,793,748.00View SEC Filing  
7/10/2015Charles S BerkmanVPSell14,067$99.14$1,394,602.38View SEC Filing  
6/26/2015Matthew W FoehrCOOSell12,500$100.97$1,262,125.00View SEC Filing  
6/22/2015Matthew W FoehrCOOSell23,046$96.45$2,222,786.70View SEC Filing  
6/10/2015Melanie J HermanCFOSell4,125$93.50$385,687.50View SEC Filing  
6/9/2015John L HigginsCEOSell10,000$92.88$928,800.00View SEC Filing  
6/4/2015Jason AryehDirectorSell1,640$92.68$151,995.20View SEC Filing  
5/20/2015Jason AryehDirectorSell9,240$87.34$807,021.60View SEC Filing  
5/14/2015Nishan M DesilvaCFOSell68,363$83.91$5,736,339.33View SEC Filing  
3/19/2015Sunil PatelDirectorSell4,591$74.42$341,662.22View SEC Filing  
2/10/2015Nishan M DesilvaVPSell2,300$56.34$129,582.00View SEC Filing  
10/15/2014John W KozarichDirectorBuy2,000$45.68$91,360.00View SEC Filing  
10/9/2014Jason AryehDirectorBuy11,000$42.99$472,890.00View SEC Filing  
8/15/2014John L HigginsCEOBuy1,000$54.97$54,970.00View SEC Filing  
6/9/2014Melanie J HermanDirectorSell1,100$69.68$76,648.00View SEC Filing  
5/27/2014Charles S BerkmanVPSell7,166$66.90$479,405.40View SEC Filing  
3/25/2014Bvf Partners P/IlInsiderSell78,226$70.09$5,482,860.34View SEC Filing  
3/19/2014Todd DavisDirectorSell7,500$79.57$596,775.00View SEC Filing  
3/18/2014John LamattinaDirectorSell5,000$78.83$394,150.00View SEC Filing  
2/20/2014Bvf Partners P/Ilmajor shareholderSell422,900$73.81$31,214,249.00View SEC Filing  
2/18/2014David KnottDirectorSell41,900$75.71$3,172,249.00View SEC Filing  
2/14/2014Jason AryehDirectorSell40,320$76.44$3,082,060.80View SEC Filing  
2/14/2014Matthew FoehrCOOSell22,500$79.54$1,789,650.00View SEC Filing  
12/12/2013Matthew FoehrCOOSell6,000$53.40$320,400.00View SEC Filing  
12/6/2013John SharpCFOSell6,000$56.08$336,480.00View SEC Filing  
10/18/2013John L HigginsCEOSell10,000$55.00$550,000.00View SEC Filing  
9/23/2013Bvf Partners P/Ilmajor shareholderSell359,023$44.50$15,976,523.50View SEC Filing  
9/12/2013David KnottDirectorSell160,000$46.78$7,484,800.00View SEC Filing  
8/30/2013Charles BerkmanVPSell28,323$47.54$1,346,475.42View SEC Filing  
8/16/2013Charles BerkmanVPSell14,583$42.63$621,673.29View SEC Filing  
8/16/2013John HigginsCEOSell10,000$42.85$428,500.00View SEC Filing  
8/16/2013John SharpCFOSell7,500$42.75$320,625.00View SEC Filing  
6/28/2013Matthew W FoehrCOOBuy1,059$17.36$18,384.24View SEC Filing  
5/10/2013Charles S BerkmanVPSell4,000$26.66$106,640.00View SEC Filing  
1/23/2013Bvf Partners L P/IlMajor ShareholderBuy39,600$19.78$783,288.00View SEC Filing  
12/14/2012Bvf Partners L P/IlMajor ShareholderBuy5,386$18.63$100,341.18View SEC Filing  
12/6/2012Bvf Partners L P/IlMajor ShareholderBuy50,100$17.94$898,794.00View SEC Filing  
12/5/2012John L HigginsCEOBuy2,000$18.03$36,060.00View SEC Filing  
10/31/2012Bvf Partners L P/IlMajor ShareholderBuy16,591$15.19$252,017.29View SEC Filing  
8/29/2012David M KnottDirectorBuy2,743$16.36$44,875.48View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Ligand Pharmaceuticals (NASDAQ LGND) News Headlines

Source:
DateHeadline
5 Top Biotech Stocks to Buy Now5 Top Biotech Stocks to Buy Now
finance.yahoo.com - December 3 at 9:43 AM
Ligand Pharmaceuticals (LGND) Downgraded by Zacks Investment ResearchLigand Pharmaceuticals (LGND) Downgraded by Zacks Investment Research
www.americanbankingnews.com - November 30 at 10:10 AM
Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)Biogen Acquires Worldwide License for Alkermes' MS Candidate (revised)
finance.yahoo.com - November 29 at 5:31 PM
Reviewing Ligand Pharmaceuticals (LGND) & Regulus Therapeutics (RGLS)Reviewing Ligand Pharmaceuticals (LGND) & Regulus Therapeutics (RGLS)
www.americanbankingnews.com - November 29 at 5:30 AM
Ligand Pharmaceuticals (LGND) PT Set at $163.00 by HC WainwrightLigand Pharmaceuticals (LGND) PT Set at $163.00 by HC Wainwright
www.americanbankingnews.com - November 28 at 11:20 AM
 Brokerages Anticipate Ligand Pharmaceuticals Incorporated (LGND) Will Announce Quarterly Sales of $45.04 Million Brokerages Anticipate Ligand Pharmaceuticals Incorporated (LGND) Will Announce Quarterly Sales of $45.04 Million
www.americanbankingnews.com - November 28 at 6:56 AM
Ligand Pharmaceuticals Incorporated (LGND) Receives Consensus Rating of "Buy" from AnalystsLigand Pharmaceuticals Incorporated (LGND) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 26 at 7:46 AM
Roth Capital Analysts Give Ligand Pharmaceuticals Incorporated (LGND) a $158.00 Price TargetRoth Capital Analysts Give Ligand Pharmaceuticals Incorporated (LGND) a $158.00 Price Target
www.americanbankingnews.com - November 25 at 5:28 PM
Ligand Pharmaceuticals (LGND) Buy Rating Reiterated at HC WainwrightLigand Pharmaceuticals' (LGND) Buy Rating Reiterated at HC Wainwright
www.americanbankingnews.com - November 22 at 4:26 PM
Ligand Pharmaceuticals Inc. (LGND) Dropped To Over A 2-Month LowLigand Pharmaceuticals Inc. (LGND) Dropped To Over A 2-Month Low
www.rttnews.com - November 22 at 1:54 AM
Ligand Pharmaceuticals Incorporated (LGND) Downgraded by Deutsche Bank AG to SellLigand Pharmaceuticals Incorporated (LGND) Downgraded by Deutsche Bank AG to Sell
www.americanbankingnews.com - November 20 at 8:52 PM
Ligand Pharmaceuticals Incorporated (LGND) PT Set at $159.00 by HC WainwrightLigand Pharmaceuticals Incorporated (LGND) PT Set at $159.00 by HC Wainwright
www.americanbankingnews.com - November 19 at 5:38 PM
Ligand Pharmaceuticals Incorporated (LGND) Stock Rating Reaffirmed by Craig HallumLigand Pharmaceuticals Incorporated (LGND) Stock Rating Reaffirmed by Craig Hallum
www.americanbankingnews.com - November 19 at 10:24 AM
Ligand Pharmaceuticals Incorporated (LGND) Director John W. Kozarich Sells 5,000 SharesLigand Pharmaceuticals Incorporated (LGND) Director John W. Kozarich Sells 5,000 Shares
www.americanbankingnews.com - November 17 at 8:12 PM
Ligand Pharmaceuticals Incorporated (LGND) VP Matthew E. Korenberg Sells 6,559 SharesLigand Pharmaceuticals Incorporated (LGND) VP Matthew E. Korenberg Sells 6,559 Shares
www.americanbankingnews.com - November 17 at 8:12 PM
Ligand Pharmaceuticals Incorporated (LGND) CEO John L. Higgins Sells 5,269 SharesLigand Pharmaceuticals Incorporated (LGND) CEO John L. Higgins Sells 5,269 Shares
www.americanbankingnews.com - November 17 at 8:11 PM
Ultragenyx's rhGUS Gets FDA Nod for Rare Genetic DiseaseUltragenyx's rhGUS Gets FDA Nod for Rare Genetic Disease
finance.yahoo.com - November 17 at 6:31 PM
Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : November 15, 2017Ligand Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LGND) : November 15, 2017
finance.yahoo.com - November 17 at 1:16 PM
Ligand Pharma (LGND) Offers Highlights from Todays Analyst Day Event - StreetInsider.comLigand Pharma (LGND) Offers Highlights from Today's Analyst Day Event - StreetInsider.com
www.streetinsider.com - November 15 at 4:07 AM
Ligand Provides Highlights from Today’s Analyst Day EventLigand Provides Highlights from Today’s Analyst Day Event
finance.yahoo.com - November 15 at 4:07 AM
Ligand Pharmaceuticals Incorporated (LGND) Issues FY17 Earnings GuidanceLigand Pharmaceuticals Incorporated (LGND) Issues FY17 Earnings Guidance
www.americanbankingnews.com - November 14 at 9:18 PM
AstraZeneca Gets Positive CHMP Opinion for Asthma CandidateAstraZeneca Gets Positive CHMP Opinion for Asthma Candidate
finance.yahoo.com - November 13 at 1:13 PM
Arena (ARNA) Completes Enrolment in Etrasimod Phase II StudyArena (ARNA) Completes Enrolment in Etrasimod Phase II Study
finance.yahoo.com - November 13 at 1:13 PM
Ligand Reports Third Quarter 2017 Financial ResultsLigand Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 11 at 4:35 PM
Ligand tops 3Q revenue forecastsLigand tops 3Q revenue forecasts
finance.yahoo.com - November 11 at 4:35 PM
Puma (PBYI) Falls Despite Narrower-Than-Expected Q3 LossPuma (PBYI) Falls Despite Narrower-Than-Expected Q3 Loss
finance.yahoo.com - November 11 at 4:35 PM
Xoma: A Lower Risk Way Of Investing In BiotechXoma: A Lower Risk Way Of Investing In Biotech
finance.yahoo.com - November 11 at 4:35 PM
Ligand Pharmaceuticals Incorporated (LGND) Issues Quarterly  Earnings ResultsLigand Pharmaceuticals Incorporated (LGND) Issues Quarterly Earnings Results
www.americanbankingnews.com - November 10 at 12:32 AM
Key Predictions for Q3 Earnings Reports of PBYI, XON, LGNDKey Predictions for Q3 Earnings Reports of PBYI, XON, LGND
finance.yahoo.com - November 8 at 1:48 PM
Prothena (PRTA) Earnings Beat in Q3, Pipeline in FocusProthena (PRTA) Earnings Beat in Q3, Pipeline in Focus
finance.yahoo.com - November 8 at 1:48 PM
Arena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales BeatArena Pharmaceuticals (ARNA) Q3 Loss Widens Y/Y, Sales Beat
finance.yahoo.com - November 8 at 1:48 PM
Alnylam's (ALNY) Q3 Earnings, Revenues Miss EstimatesAlnylam's (ALNY) Q3 Earnings, Revenues Miss Estimates
finance.yahoo.com - November 8 at 1:48 PM
Keryx (KERX) Q3 Loss Wider Than Expected, Stock DeclinesKeryx (KERX) Q3 Loss Wider Than Expected, Stock Declines
finance.yahoo.com - November 8 at 1:48 PM
Agenus (AGEN) Reports In Line Loss in Q3, Revenues LagAgenus (AGEN) Reports In Line Loss in Q3, Revenues Lag
finance.yahoo.com - November 8 at 1:48 PM
What's in Store for Ligand (LGND) This Earnings Season?What's in Store for Ligand (LGND) This Earnings Season?
finance.yahoo.com - November 6 at 8:46 PM
Reminder: Ligand to Host Analyst Day on November 14th in New York CityReminder: Ligand to Host Analyst Day on November 14th in New York City
finance.yahoo.com - November 6 at 3:41 PM
Ligand Pharmaceuticals (LGND) versus Asterias Biotherapeutics (AST) Head to Head ComparisonLigand Pharmaceuticals (LGND) versus Asterias Biotherapeutics (AST) Head to Head Comparison
www.americanbankingnews.com - November 5 at 3:40 PM
Is It Time To Buy Ligand Pharmaceuticals Incorporated (LGND)?Is It Time To Buy Ligand Pharmaceuticals Incorporated (LGND)?
finance.yahoo.com - November 5 at 5:07 AM
Strange: Bullish LGND Analysts Actually See -1.3% DownsideStrange: Bullish LGND Analysts Actually See -1.3% Downside
www.nasdaq.com - November 4 at 5:47 AM
Ligand to Participate in the Stephens Fall Investment ConferenceLigand to Participate in the Stephens Fall Investment Conference
finance.yahoo.com - November 4 at 5:47 AM
AMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 OutlookAMAG Pharma's (AMAG) Q3 Earnings Beat, Lowers '17 Outlook
finance.yahoo.com - November 3 at 2:40 PM
PDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/YPDL BioPharma (PDLI) Q3 Earnings Beat, Revenues Rise Y/Y
finance.yahoo.com - November 3 at 2:40 PM
Ligand Pharmaceuticals Incorporated (LGND) to Release Quarterly Earnings on ThursdayLigand Pharmaceuticals Incorporated (LGND) to Release Quarterly Earnings on Thursday
www.americanbankingnews.com - November 2 at 3:32 AM
Ligand Pharmaceuticals Incorporated (LGND) Receives Average Recommendation of "Buy" from BrokeragesLigand Pharmaceuticals Incorporated (LGND) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - November 1 at 10:24 AM
Ligand to Report Third Quarter 2017 Results on November 9thLigand to Report Third Quarter 2017 Results on November 9th
finance.yahoo.com - October 25 at 6:41 AM
3 Small, Profitable Biotechs With Fantastic Growth3 Small, Profitable Biotechs With Fantastic Growth
www.fool.com - October 24 at 7:57 AM
Zacks: Brokerages Anticipate Ligand Pharmaceuticals Incorporated (LGND) Will Post Quarterly Sales of $31.22 MillionZacks: Brokerages Anticipate Ligand Pharmaceuticals Incorporated (LGND) Will Post Quarterly Sales of $31.22 Million
www.americanbankingnews.com - October 21 at 10:52 AM
Ligand Pharmaceuticals Incorporated (LGND) Given a $157.00 Price Target by HC Wainwright AnalystsLigand Pharmaceuticals Incorporated (LGND) Given a $157.00 Price Target by HC Wainwright Analysts
www.americanbankingnews.com - October 18 at 8:58 PM
Zacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand PharmaceuticalsZacks Industry Outlook Highlights: Novo, Vertex Pharmaceuticals, Celgene and Ligand Pharmaceuticals
finance.yahoo.com - October 18 at 4:04 PM
Impax Laboratories and Amneal Pharmaceuticals Agree to MergeImpax Laboratories and Amneal Pharmaceuticals Agree to Merge
finance.yahoo.com - October 18 at 4:04 PM

SEC Filings

Ligand Pharmaceuticals (NASDAQ:LGND) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Ligand Pharmaceuticals (NASDAQ:LGND) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Ligand Pharmaceuticals (NASDAQ LGND) Stock Chart for Wednesday, December, 13, 2017

Loading chart…

This page was last updated on 12/13/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.